• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    WASHING SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY. The present invention relates to a washing method for affinity chromatography in which a washing solution comprising arginine, or an arginine derivative, and an un-buffered salt, preferably at a high pH, greater than 8.0, is effective in the removal of impurities, such as high molecular weight species and host cell proteins, while also increasing the product concentration in the eluate and maintaining a high percentage yield of recovered product.
    公开号:BR112012014937B1
    申请号:R112012014937-7
    申请日:2010-12-17
    公开日:2021-01-19
    发明作者:Achim Frauenschuh；Kurt Bill
    申请人:Novartis Ag；
    IPC主号:
    专利说明:

    Background of the Invention
    [001] Affinity chromatography allows the purification of a protein of interest from a mixture of molecules, such as a cell harvest, based on the preferential binding of the protein of interest to a solid phase target, such as a matrix of gel. This solid phase component is typically formed in a column through which the mixture containing the protein of interest is applied. In this initial stage, the so-called capture stage, the protein of interest specifically binds to the target in the solid phase while other components in the mixture flow through the column. However, certain components within the mix, including high molecular weight species (HMWs), low molecular weight species (LMWs) and host cell proteins (HCPs), can remain inside the column as impurities, along with the protein from interest. Thus, typically one or more washing steps are carried out in which one or more washing solutions are applied to the column to remove these impurities, maintaining the binding of the protein of interest to the solid phase. Finally, after the removal of impurities by the washing step (s), the protein of interest is recovered from the column by an elution step, in which an elution solution that interrupts the binding of the protein of interest to the phase target solid is applied to the column and the protein of interest is recovered in the eluate. Therefore, the effectiveness of affinity chromatography when purifying a protein of interest depends, in large part, on the identification of washing conditions that allow efficient removal of impurities (for example, HMWs, LMWs, HCPs), while not disrupting binding of the protein of interest to the solid phase target or otherwise having undesirable effects.
    [002] A particularly useful type of affinity chromatography is Protein A chromatography for the purification of proteins that contain an immunoglobulin Fc region, such as antibodies and Fc fusion proteins. Various washing solutions have been described for removing impurities from Protein A columns, including washing solutions containing one of the following: hydrophobic electrolytes (for example, tetramethylammonium chloride, tetraethylammonium chloride, tetrapropylammonium chloride or tetrabutylammonium, with pH 5.0 to 7.0), solvents (for example, 5 to 20% isopropanol or polypropylene / hexylene glycol), urea (for example, a concentration of 1 to 4 M), detergents (for example, 0.1 to 1% Tween 20 or Tween 80), polymers (for example, 5-15% polyethylene glycol, such as PEG400 or PEG8000) or highly concentrated buffer solutions, such as Tris, HCl, acetate, sulfate, phosphate or citrate buffers in a concentration of 0.8 to 2.0 M at a pH between 5.0 and 7.0 (see, for example, Shukla, AA and Hinckley, P. (2005) Biotechnol Prog. 24: 1115 -1121; US Patent 6,127,526 and 6,333,398 to Blank, and US Patent 6,870,034 to Breece et al). Many of these chemicals, however, have one or more disadvantages, including, but not limited to, toxicity, flammability, corrosivity, instability, expensive disposal as hazardous waste and / or inefficient contaminant removal during the wash step.
    [003] Protein chromatography wash buffer solutions containing salt (such as sodium chloride), alone or in combination with either a detergent (eg Tween 20), a solvent (eg hexylene glycol) or a polymer (eg, polyethylene glycol), have also been described (US Patent 6,870,034 to Breece et al.).
    [004] Barron et al. describe an intermediate wash solution for Protein A chromatography containing 0.5 to 2.0 M arginine in a phosphate / acetate buffer solution with pH 5.0-7.5 (optimally 1M arginine, phosphate / acetate buffer 0.1M at pH 5.0). This arginine wash step is reported to remove contaminants from HCP. The authors also tested an intermediate wash solution that contained 0.5 to 2.0 M sodium chloride with pH 5.0 to 7.5, but reported that the NaCl wash solution did not show any significant decrease in HCP ( Barron et al., "Improving Purity in Media with Protein A affinity through the use of an Intermediate Arginine wash step", http://www.priorartdatabase.com/IPCOM/000127319).
    [005] Sun et al. also describe washing the affinity chromatography columns, such as a Protein A Column, with a wash buffer solution containing arginine, or an arginine derivative, at a concentration of 0.1 to 2.0 M and with a pH 4.5 to 8.0 (US Patent Publication 20080064860 and 20080064861; PCT Publication WO 2008/031020).
    [006] Arginine has also been used to elute proteins from affinity chromatography columns and other types of purification columns. For example, Arakawa et al. describe methods for eluting antibodies from a Protein A column using an elution buffer solution containing 0.5 to 2.0 M with pH 4.1 to 5.0 arginine (Arakawa et al (2004) Protein Expression and Purification 36: 244-248; Tsumoto, K. et al (2004) Biotechnol Prog 20: 1301-1308; US Patent Publication 20050176109). In addition, US Patent 7,501,495 to Ejima et al. describes methods of eluting proteins from a gel filtration column using a developing solution containing arginine hydrochloride. Ghose et al. describe methods of eluting proteins of interest from non-derivative silica using an arginine gradient as an eluent (Ghose, S. et al. (2004) Biotech. Bioeng. 87: 413-423). US Patent Publication 20030050450 by Coffman et al. describes methods of dissociating Fc containing molecules from Fc complexes containing molecule and Protein A, in which the Fc / Protein A complexes are applied to a hydrophobic interaction column (HIC) and the column is washed with a buffer solution containing arginine. Summary of the Invention
    [007] This invention provides an efficient and robust washing solution for affinity chromatography, as well as washing methods using this solution. This washing solution is applied in a washing step before the elution step, and its use results in high yields and high concentrations of the protein of interest eluted from the affinity matrix, while effectively removing both high molecular weight species ( HMWs) and host cell proteins (HCPs) from the starting material applied to the matrix. This washing solution is characterized by the presence of both arginine (or an arginine derivative) and an un-buffered salt, such as a halogen salt. Preferably, the washing solution has a high pH, above 8.0. This combination of arginine (or an arginine derivative) and an un-buffered salt removes impurities considerably more than washing solutions containing either arginine or salt alone and results in a sharper elution peak correlating with a high concentration of recovered protein of interest.
    [008] Therefore, in one aspect, the invention provides a method of producing a purified protein of interest using an affinity chromatography (AC) matrix, to which a protein of interest is bound, the method comprising washing the matrix of AC with one or more washing solutions comprising (i) arginine, or an arginine derivative, and (ii) an un-buffered salt, before the elution of the protein of interest from the AC matrix. Preferably, the protein of interest is loaded onto the AC matrix prior to washing with one or more washing solutions and the protein of interest is eluted from the AC matrix after washing with one or more washing solutions, in particular , to remove impurities from the AC matrix.
    [009] In a preferred embodiment, the AC matrix is a Protein A column. In several other embodiments, the AC matrix can be, for example, selected from the group consisting of a Protein G column, a column of Protein A. protein A / G, a protein L column, an immobilized metal ion affinity chromatography (IMAC) column, a calmodulin resin column, a MEP HyperCel® column, a column that binds to the maltose binding protein (MBP), a column that binds to glutathione-S-transferase (GST) and a column that binds to Strep-Tag II. In a preferred embodiment, the protein of interest is an antibody or antibody fragment that binds to the AC matrix, such as a Protein A Column, although other proteins that bind to the affinity matrices described herein are also suitable for purification according to the methods of the invention.
    [0010] In a preferred embodiment, the one or more washing solutions comprise arginine-HCl, preferably at a concentration in the range of 0.05 to 2.0 M, more preferably in the range of 0.05-0, 85 M, more preferably in a range of 0.1 to 0.5 M. In particular embodiments, arginine-HCl is present in a concentration of 0.1 M or about 0.1 M, 0.25 M or about 0.25 M, or 0.5 M or about 0.5 M. In other embodiments, the one or more washing solutions comprise an arginine derivative, such as a derivative selected from the group consisting of acetyl-arginine, N -alpha-butyryl-arginine, agmatine, arginic acid and N-alpha-pivaloyl-arginine. Preferably, the arginine or arginine derivative comprises L-arginine, although D-arginine is also covered.
    [0011] In a preferred embodiment, the non-buffered salt in one or more washing solutions is sodium chloride (NaCl), preferably in a concentration in the range of 0.1 to 2.0 M. In particular embodiments, NaCl is present at a concentration of 0.75 M or about 0.75 M, 1.0 M or about 1.0 M, or 1.25 M or about 1.25 M. In other embodiments, the un-buffered salt in one or more washing solutions it is selected from the group consisting of potassium chloride, calcium chloride and magnesium chloride.
    [0012] In a particular embodiment, the pH of one or more washing solutions is greater than 8.0, preferably at least 8.1, more preferably at least 8.5 and, even more preferably at least 8.9. In one embodiment, the pH of one or more washing solutions is in the range of 8.1-9.5. In another embodiment, the pH of one or more washing solutions is in the range of 8.5 to 9.5. In another embodiment, the pH of one or more washing solutions is about 9.0. In another embodiment, the pH of one or more washing solutions is 9.0.
    [0013] The combination of arginine wash and the non-buffered salt described here is preferably applied to a single wash solution containing both components (ie the AC matrix is washed with a wash solution comprising either arginine (i) or an arginine derivative, and (ii) an un-buffered salt). Alternatively, two washing solutions, an arginine containing or an arginine derivative (preferably, with a pH greater than 8.0) and the other containing an un-buffered salt can be used in tandem washes. Therefore, in another mode of the washing method, the AC matrix is washed with two washing solutions, a first washing solution and a second washing solution. In one embodiment, the washing solution comprises first arginine, or an arginine derivative, and the second washing solution comprises an un-buffered salt. In another embodiment, the first washing solution comprises an un-buffered salt and the second washing solution comprises arginine or an arginine derivative.
    [0014] The washing method of the present invention is effective in removing a variety of impurities, including high molecular weight species (HMW) and host cell proteins (HCPs).
    [0015] In another aspect, the invention provides a method of producing a purified antibody, or antibody fragment, using a Protein A column, the method comprising (a) loading a mixture comprising the antibody, or antibody fragment, for the Protein A column; (b) washing the protein A column with a washing solution comprising (i) Arginine-HCl, in a concentration in the range of 0.05-2.0 M (more preferably, 0.050.85 M, more preferably, 0 , 1-0.5 M), and sodium chloride, in a concentration in a range of 0.1-2.0 M, in which the washing solution removes the impurities from the Protein A column, and (c), eluting the antibody, or antibody fragment, from the Protein A Column. In particular embodiments, arginine-HCl is present in a concentration of 0.1 M or about 0.1 M, 0.25 M or about 0.25 M, or 0.5 M or about 0.5 M. In particular embodiments, NaCl is present in a concentration of 0.75 M or about 0.75 M, 1.0 M or about 1, 0 M, or 1.25 M or about 1.25 M. In various embodiments, the pH of the washing solution is greater than 8.0, preferably at least 8.1, more preferably at least 8.5, more preferably 9.0, in a range of 8.1 to 9.5, or in a range of 8.5 to 9.5. Detailed Description of the Invention
    [0016] The invention provides a new washing solution for affinity chromatography, such as Protein A chromatography, which is applied to the column prior to the elution of the protein of interest to remove impurities. The new wash solution is made up of arginine, or an arginine derivative, and an un-buffered salt. Typically, the washing solution is an aqueous solution.
    [0017] As used herein, the term "un-buffered salt" refers to a salt that is present in the washing solution that is of a type, and in a concentration, such that it does not contribute substantially to retain the pH of the washing solution under applied conditions (such as high pH) by adding acid or base. Typically, non-buffered salt is an ionic salt. Unbuffered salts include halogen salts, including those comprising Cl or Br (more preferably, Cl), in particular halogen salts comprising alkali metals or alkaline earth metals, including Na, K, Ca and Mg (more preferably Na or K) . The term "non-buffered salt" does not include buffered salts, such as sodium acetate, sodium phosphate and Tris, which effectively contribute to substantially retaining the pH of a washing solution under the applied conditions. In a preferred embodiment, the salt is an un-buffered halogen salt (for example, comprising Cl or Br). In another embodiment, the salt is a non-buffered halogen salt, which comprises sodium (Na), potassium (K), calcium (Ca) or magnesium (Mg), more preferably, sodium (Na) or potassium (K). In yet another embodiment, the non-buffered salt is selected from the group consisting of NaCl, KCl, CaCl2 and MgCl2. In a particularly preferred embodiment, the un-buffered salt is sodium chloride (NaCl). Typically, non-buffered salt is used at a "high" concentration of at least 1 M. Other suitable concentrations and concentration ranges are described below.
    [0018] This new combination of washing components removes impurities considerably more than the commonly used procedures without affecting recovery. In addition, this washing condition results in a clearer elution peak, correlating with a higher concentration of the protein of interest in the eluate, which is advantageous for increasing the performance of additional downstream purification processes.
    [0019] Efficient removal of impurities, including host cell proteins (HCPs) and product-related impurities, such as high molecular weight species (HMW) and low molecular weight species (LMW), is a crucial factor during downstream processing of a protein of interest. Affinity chromatography is often used as the first step in a multistage purification process for a protein of interest (for example, an antibody) and the purity of the protein of interest, after affinity chromatography, in particular influences the type and the number of subsequent purification steps. Another important function for affinity chromatography is the concentration of the product, which allows the use of less expensive, proportionally smaller columns in subsequent purification steps. Therefore, it is particularly important to optimize the removal of impurities during the affinity chromatography step.
    [0020] Low pH conditions, typically between pH 3 - 4, are a requirement to elute the bound protein of interest from the affinity matrix and have the drawback of being able to cause aggregation. Historically, less stringent conditions, such as pH 5 - 5.5, have been used to wash the unspecifically bound impurities from the column, preserving the interaction between the protein of interest and the affinity matrix. The recovery of the protein of interest, however, is often diminished due to the partial elution of the protein of interest under these conditions, especially when working at high charge densities. Therefore, in a preferred embodiment, the washing solution provided by the present invention is advantageously carried out at a high pH, greater than 8.0, which preserves the binding of the protein of interest to the affinity matrix, while allowing the removal of impurities.
    The new washing solution for affinity chromatography provided by the present invention is based on a mixture of arginine (or arginine derivative) and an un-buffered salt, preferably carried out at a high pH. The great biophysical diversity of impurities present in common productions or cell extracts results in very different modes of interactions with the solid phase of the chromatography medium and / or the bound protein of interest. More or less strong strings of impurities can be the result of non-covalent intermolecular interactions between the two molecules, such as hydrogen bonding, electrostatic, hydrophobic interactions and Van der Waals forces, or a combination of these types of interactions. Therefore, a combination of several different mechanisms for removing impurities is likely to be much more effective than an approach based on a single mechanism for removing impurities.
    [0022] Regarding the effects of the non-buffered salt in the washing solution, based on the analytical data described here, the high affinity interactions between the protein of interest and the affinity matrix ligand are not broken by a washing in concentrations elevated un-buffered salines, while charged contaminants tied not specifically to waste loaded in any immobilized ligand or bound protein of interest are removed efficiently. Therefore, although not intended to be limited by mechanism, it is believed that the non-buffered salt used in the washing solution has the ability to break down ionic interactions between charged contaminants (impurities) tied not specifically to waste loaded in one or more components of the matrix affinity chromatography (for example, the matrix chemical support such as a resin, the affinity ligand immobilized on the matrix and / or the target of interest attached to the ligand immobilized on the matrix), while not disturbing the specific binding of the bound target to the immobilized ligand.
    [0023] Regarding the effects of arginine in the washing solution, it has been reported that arginine is capable of solubilizing certain precipitated proteins (Umetsu, M. et al (2005) Biochem Biophys Res Commun 328: 189-197; Tsumoto, K. et al (2003) Biochem. Biophys. Res. Commun. 312: 1383-1386), reduce the formation of aggregates (Arakawa, T. et al. (2003) Biochem. Biophys. Res. Commun. 304: 148- 152), and reduce non-specific protein adsorption to surfaces (Ejima, D. et al. (2005) J. Chromatogr. A. 1094: 49-55). Although not intended to be limited by the mechanism, the reduction in protein aggregation may be due to the masking of hydrophobic spots on proteins, which interact with arginine. This interaction can happen between the guanidine group in arginine and tryptophan groups in proteins, or through the formation of a hydrophobic stain by agglomeration of arginine, or it can be a combination of such effects.
    [0024] Regarding the use of a pH greater than 8.0 in the washing solution, a basic pH can partially denature HCPs and HMWs, while stable proteins including monomeric antibodies are not influenced in such conditions. Although not intended to be limited by the mechanism, the denaturation of the contaminating proteins can be manifested as a slight change in structure, which may be sufficient to weaken the non-specific binding. Therefore, the high pH of the washing solution can be beneficial in increasing the removal of impurities to destabilize its interaction with the bound protein of interest or the solid support of the affinity matrix.
    [0025] Therefore, in one aspect, the invention provides a method of producing a purified protein using an affinity chromatography (AC) matrix, to which a protein of interest is attached, the method comprising washing the AC matrix with one or more washing solutions comprising (i) arginine, or an arginine derivative, and (ii) an un-buffered salt, before the elution of the protein of interest from the AC matrix.
    [0026] As used herein, the term "affinity chromatography matrix" or "AC matrix" is intended to refer to a solid phase medium, typically a gel or resin, which allows the separation of biochemical mixtures based on in a highly specific binding interaction between a protein of interest and the AC matrix, such as between a receptor and ligand, enzyme and the substrate or antigen and antibody. Thus, the solid phase medium comprises a target to which the protein of interest is capable of reversibly attaching itself, depending on the buffer conditions. Non-limiting examples of immobilized or solid phase medium that may comprise the AC matrix include a gel matrix, such as agarose beads (such as commercially available Sepharose matrices), and a glass matrix, such as porous glass beads (such as commercially available Prosep matrices).
    [0027] The binding of the protein of interest to the AC matrix is typically achieved by column chromatography. That is, the AC matrix is formed within a column, a biochemical mixture containing a protein of interest is flowed through the column, followed by washing the column by means of flow through the column, one or more washing solutions, followed by elution of the protein of interest from the column, flowing through the column, an elution buffer solution.
    [0028] Alternatively, the binding of the protein of interest to the AC matrix can be achieved by batch treatment, in which the biochemical mixtures containing the protein of interest are incubated with the AC matrix in a container to allow the binding of the protein of interest to the AC Matrix, the solid phase medium is removed from the container (for example, by centrifugation), the solid phase medium is washed to remove impurities and, again, recover (for example, by centrifugation) and the protein of interest is eluted from the solid phase medium.
    [0029] In yet another embodiment, a combination of batch treatment and column chromatography can be used. For example, the initial binding of the protein of interest to the AC matrix can be achieved by batch treatment and then the solid phase medium can be packaged in a column, followed by washing the column and eluting the protein of interest. from the column.
    [0030] The nature of a particular solid phase matrix, in particular the binding properties of the target bound to the solid phase, determines the type (s) of protein (s) that can be purified using the phase matrix solid. For example, in a preferred embodiment of the invention, the AC matrix is a Protein A column, comprising as the target bound to the solid phase a protein from the bacterial cell wall, Protein A, which specifically binds the CH2 and CH3 within the Fc region of certain immunoglobulins. The binding properties of protein A are well established in the art. Therefore, in a preferred embodiment of the invention, the protein of interest (to be purified) is an antibody or antibody fragment comprising an Fc region. In addition, additional proteins that can be purified using protein A chromatography include Fc fusion proteins. Insofar as any protein is able to specifically bind to a protein A matrix, it can be purified according to the methods of the invention.
    [0031] Various Protein A resins are well known in the art and suitable for use in the invention. Non-limiting examples of commercially available Protein A resins include MabSelect, MabSelect Xtra, MabSelect Sure, rProtein A Sepharose FF, rmpProtein A Sepharose FF, Protein A-Sepharose CL-4B and nProtein A Sepharose 4 FF (all commercially available from GE Healthcare) ; ProSep A, high-capacity Prosep-vA, ProSep-vA Ultra and ProSep-Va Ultra Plus (all commercially available from Millipore); Poros A and Mabcapture A (both commercially available from Poros); IPA-300, IPA-400 and IPA-500 (all commercially available from Repligen Corp.); Affigel protein A and Affiprep protein A (both commercially available from Bio-Rad); MABsorbent A1P and MABsorbent A2P (both commercially available from Affinity Chromatography Ltd.); Protein A Ceramics Hyper DF (commercially available from Pall Corporation); Ultralink Immobilized protein A and Agarose protein A (both commercially available from PIERCE); and Protein A Cellthru 300 and Proein A Ultraflow (both commercially available from Sterogen Bioseparations).
    [0032] In addition to Protein A chromatography, the washing method of the present invention can be applied to other affinity chromatography systems. For example, in another embodiment, the AC matrix may be a protein G column, a Protein A / G column or a protein L column, each of which are also immunoglobulin-binding bacterial proteins with properties of connections established in the art. Thus, an AC matrix that is a protein G matrix, a protein A / G matrix or a protein L matrix can be used to purify antibodies, antibody fragments comprising an Fc region and Fc fusion proteins.
    [0033] Other non-limiting examples of AC matrices, and the types of proteins that are effective in purification include the following: an immobilized metal ion affinity chromatography column (IMAC) (for the purification of proteins with an affinity for the metal ions, such as histidine-labeled proteins), a column of calmodulin resin (for the purification of proteins labeled with calmodulin-binding peptide (CBP)), a column of MEP HyperCel® (a cellulose matrix that selectively binds immunoglobulin ), a column that binds to maltose-binding protein (MBP) (such as a SepharoseTM dextrin resin that selectively binds MBP-labeled proteins), a column that binds glutathione-S-transferase (GST) (such as a resin SepharoseTM glutathione that selectively binds GST-tagged proteins) and a column that binds Strep-Tag II (such as a Sepharose Strep-TactinTM resin that selectively binds Strep-Tag II-tagged proteins). In addition, immunoaffinity matrices, which comprise an antibody as the target attached to the solid phase, can be used to purify an antigen of interest that specifically binds to the antibody attached to the solid phase.
    [0034] Although the invention of interest is described herein, in particular with regard to the purification of antibodies using protein A chromatography, as any protein is known in the art to selectively bind to a given AC matrix, the protein is capable of purification using the washing methods described herein.
    [0035] The washing solutions of the invention comprise arginine or an arginine derivative. Arginine, which can be used in the present invention, can be natural amino acid arginine (e.g., L-arginine), D-arginine or an arginine derivative. Non-limiting examples of arginine derivatives include acylated arginine, such as acetyl arginine and N-alpha-butyryl-arginine, agmatine, arginic acid and N-alpha-pivaloyl arginine. Arginine or an arginine derivative can be used in the form of an acid addition salt. Examples of the acid that can form an acid addition salt include hydrochloric acid and the like.
    [0036] The concentration of arginine or arginine derivative in the washing solution is typically between 0.05 M and 2.0 M (for example, 0.05 M, 0.1 M, 0.15 M, 0.2 M , 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0.45 M, 0.5 M, 0.55 M, 0.6 M, 0.65 M, 0.7 M , 0.75 M, 0.8 M, 0.85 M, 0.9 M, 0.95 M, 1.0 M, 1.1 M, 1.15 M, 1.20 M, 1.25 M , 1.30 M, 1.35 M, 1.40 M, 1.45 M, 1.5 M, 1.55 M, 1.6 M, 1.65 M, 1.7 M, 1.75 M , 1.8 M, 1.85 M, 1.9 M, 1.95 M, or 2.0 M), more preferably between 0.05 M and 0.85 (which is the superior solubility of arginine in water at 20 ° C) (e.g. 0.05 M, 0.1 M, 0.15 M, 0.2 M, 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0, 45 M, 0.5 M, 0.55 M, 0.6 M, 0.65 M, 0.7 M, 0.75 M, 0.8 M or 0.85 M), more preferably, between 0, 1 and 0.5 M (for example, 0.1 M, 0.15 M, 0.2 M, 0.25 M, 0.3 M, 0.35 M, 0.4 M, 0.45 M or 0.5 M). In various embodiments, the concentration of arginine or arginine derivative can be, for example, 0.05 M, 0.1 M, 0.2 M, 0.25 M, 0.3 M, 0.4 M, 0, 5 M, 0.6 M, 0.7 M or 0.8 M, or between 0.1 M and 0.5 M. In certain embodiments, the concentration of arginine or arginine derivative in the washing solution is 0, 25 M or higher. In particular embodiments, arginine is present at a concentration of 0.1 M or about 0.1 M, 0.25 M or about 0.25 M, or 0.5 M or about 0.5 M.
    [0037] The washing solutions of the present invention also comprise an un-buffered salt, as described above, which is of a type and in a concentration sufficient to break ionic interactions between the impurities and one or more components of the affinity matrix. In a preferred embodiment, the salt is an un-buffered halogen salt. In a particularly preferred embodiment, the un-buffered salt is sodium chloride (NaCl). In other embodiments, the non-buffered salt can be, for example, potassium chloride (KCl), calcium chloride (CaCl2) or magnesium chloride (MgCl2). The concentration of un-buffered salt in the washing solution is typically between 0.1 M and 2.0 M (for example, 0.1 M, 0.15 M, 0.2 M, 0.25 M, 0.3 M , 0.35 M, 0.4 M, 0.45 M, 0.5 M, 0.55 M, 0.6 M, 0.65 M, 0.7 M, 0.75 M, 0.8 M , 0.85 M, 0.9 M, 0.95 M, 1.0 M, 1.1 M, 1.15 M, 1.20 M, 1.25 M, 1.30 M, 1.35 M , 1.40 M, 1.45 M, 1.5 M, 1.55 M, 1.6 M, 1.65 M, 1.7 M, 1.75 M, 1.8 M, 1.85 M , 1.9 M, 1.95 M, or 2.0 M), or between 0.5 M and 1.5 M (for example, 0.5 M, 0.55 M, 0.6 M, 0, 65 M, 0.7 M, 0.75 M, 0.8 M, 0.85 M, 0.9 M, 0.95 M, 1.0 M, 1.1 M, 1.15 M, 1, 2 M, 1.25 M, 1.3 M, 1.35 M, 1.4 M, 1.45 M, or 1.5 M), or between 1 M and M 2 (for example, 1 M, 1 , 1 M, 1.15 M, 1.2 M, 1.25 M, 1.3 M, 1.35 M, 1.4 M, 1.45 M, 1.5 M, 1.55 M, 1 , 6 M, 1.65 M, 1.7 M, 1.75 M, 1.8 M, 1.85 M, 1.9 M 1.95 M, or 2 M). In certain embodiments, the concentration of un-buffered salt in the washing solution is 1 M or higher. In particular embodiments, the non-buffered salt in the washing solution is present at a concentration of 0.75 M or about 0.75 M, 1.0 M or about 1.0 M, or 1.25 M or about 1.25 M.
    [0038] The pH of the washing solutions of the present invention is typically greater than 8.0, although lower pHs are also suitable for use with the washing solution of the invention. In a particular embodiment, the pH is greater than 8.0, preferably at least 8.1, more preferably at least 8.5 or 8.9. In one embodiment, the pH of one or more washing solutions is in the range of 8.1-9.5. In another embodiment, the pH of one or more washing solutions is in the range of 8.5-9.5. In another embodiment, the pH of one or more washing solutions is about 9.0. In another embodiment, the pH of one or more washing solutions is 9.0. Alternatively, depending on the protein of interest to be purified, a lower pH value can be used, for example a pH in the pH range 5.0 to 8.0, or a pH of 7.5 or 7.0 or 6 , 5, or 5.0. Depending on the properties of the protein to be purified, those skilled in the art can select an appropriate pH value for the washing solution. Therefore, the wash solution (s) may contain one or more buffers for regulation and / or maintaining the pH. Non-limiting examples of typical buffers that can be included in the wash solution (s) include Tris (tris (hydroxymethyl) methylamine), bis-Tris, bis-Tris propane, histidine, triethanolamine, diethanolamine, format, acetate, MES (2- (N-morpholino) ethanesulfonic), phosphate, HEPES (4-2-hydroxyethyl-1-piperazinoethanesulfonic), citrate, MOPS (3- (N-morpholino) propanesulfonic), TAPS (3 - {[tris (hydroxymethyl)) methyl ] -amino} propanesulfonic), bicin (N, N-bis (2-hydroxyethyl) glycine), Tricine (N-tris (hydroxymethyl) methylglycine), TES (2 - {[tris (hydroxymethyl) methyl] -amino} ethanesulfonic acid ), PIPES (piperazine-N, N'-bis (2-ethanesulfonic), cacodylate (dimethylarsinic acid) and SSC (saline sodium citrate).
    [0039] The combination of arginine wash and non-buffered salt described here is preferably applied to a single wash solution containing both components. Alternatively, two washing solutions, one containing arginine or an arginine derivative (preferably at a high pH) and the other containing an un-buffered salt can be used in tandem washes. Therefore, in another mode of the washing method, the AC matrix is washed with two washing solutions, a first washing solution and a second washing solution, before the elution of the protein of interest. In one embodiment, the first wash solution comprises arginine, or an arginine derivative, (preferably at a pH greater than 8.0) and the second wash solution comprises an un-buffered salt. In another embodiment, the first washing solution comprises an un-buffered salt and the second washing solution comprises arginine, or an arginine derivative, (preferably at a pH greater than 8.0). Examples of arginine derivatives and suitable un-buffered salts, as well as the preferred concentrations, concentration ranges and pH conditions for the washing solutions are as described above.
    [0040] The washing method of the present invention is effective in removing a variety of impurities, including high molecular weight species (HMW) and host cell proteins (HCPs). As described in detail in the examples, the washing solutions of the present invention are effective in reducing both species of HMW and HCPs in the eluate, by achieving a high percentage yield of the protein of interest in the eluate and a high concentration of protein of interest in the eluate. eluted. For example, in various embodiments, the use of the washing method described herein results in a percentage yield of the protein of interest that is greater than 95%, more preferably greater than 96%, even more preferably greater than 97%. Regarding the reduction of the HMW species in the eluate, which can be expressed as the% HMW in the eluate, in various modalities the use of the washing method described here results in a% HMW in the eluate that is less than 10%, or less than 5%, or less than 2.0%, or less than 1% or less than 0.5%. With regard to the reduction of HCPs in the eluate, which can be expressed as the logarithmic reduction value (LRV), in several modalities, the use of the washing method described here results in an LRV for HCPs in the eluate which is at least 1 , 1, or at least 1.3, or at least 1.5, or at least 2.0, or at least 2.3, or at least 2.5, or at least 2.7.
    [0041] Although the invention is described here with respect to a washing step during affinity chromatography, it will be readily apparent to ordinarily skilled specialists that the additional steps are carried out before and after the washing step to achieve the purification of the protein of interest from the affinity chromatography matrix. For example, prior to the washing step, the methods of the invention may include a balancing step, in which the affinity chromatography matrix is equilibrated with a loading buffer solution, and a loading or capture step, in which a mixture Biochemical (for example, cell harvest) containing the protein of interest is applied to the CA matrix. The appropriate conditions for the balance and loading buffer solutions will vary, depending on the nature of the AC matrix and the protein of interest to be purified, and those skilled in the art can readily determine such conditions, using methods and information well established in the art . Non-limiting examples of balancing and loading buffer solutions for the purification of antibodies on the Protein A column are shown in Examples 1 and 2. Furthermore, after the washing step (s) as mentioned above, the methods of the invention may include one or more washes additional step (s) using standard washing solutions, and / or an elution step, in which an elution buffer solution is applied to the affinity chromatography matrix to elute the protein of interest from the matrix . The appropriate conditions for the elution buffer will vary, depending on the nature of the AC matrix and the protein of interest to be purified, and the ordinarily skilled person can readily determine such conditions, using methods and information well established in the art. Typically, the elution of the protein of interest from the AC matrix is performed at an acidic pH. N limiting examples of an elution buffer solution for the purification of antibodies in the Protein A column are given in Examples 1 and 2.
    [0042] In another aspect, the invention provides preferred methods for removing impurities from mixtures containing antibodies during the purification of protein A from the antibody. Accordingly, the invention provides a method of producing a purified antibody, or antibody fragment, using a Protein A column, the method comprising a) loading a mixture comprising the antibody, or antibody fragment, to the Protein A column ; b) wash the Protein A Column with a washing solution comprising (i) Arginine-HCl in a concentration in the range of 0.05 to 2.0 M (more preferably in the range of 0.05 to 0.85 M , more preferably in a range of 0.1 to 0.5 M) and (ii) sodium chloride, in a concentration in a range of 0.1 to 2.0 M, in which the washing solution removes impurities from the Protein A column, and c) eluting the antibody, or antibody fragment, from the Protein A column.
    [0043] Preferably, the wash solution is at a pH greater than 8.0. Preferred concentrations and concentration ranges for arginine-HCl are as described above. For example, in a preferred embodiment, arginine-HCl is at a concentration of about 0.25 M or at a concentration of 0.25 M. The preferred concentrations and concentration ranges for sodium chloride are as described above. For example, in a preferred embodiment, sodium chloride is at a concentration of about 1 M or at a concentration of 1 M. Preferred pHs and pH ranges are also as described above. For example, in one embodiment, the pH of the washing solution is in the range of 8.1-9.5. In another embodiment, the pH of the washing solution is 8.5 or higher. In another embodiment, the pH of the washing solution is 9.0.
    [0044] The present invention is further illustrated by the following examples, which should not be construed as further limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby expressly incorporated by reference in their entirety. EXAMPLES Example 1: Comparison of Arginine / Unbuffered Salt Wash Solution with other wash solutions
    [0045] In this example, the effectiveness of various washing solutions for removing impurities from a solution containing antibodies during affinity chromatography is compared. More specifically, three washing solutions are compared: one that does not contain arginine and no non-buffered salt at pH 5.0, the second non-buffered salt containing arginine, but not pH 7.0, and the third containing both non-buffered salt buffered and arginine with pH 9.0.
    [0046] Culture supernatants from clarified mammalian cells containing between 1.5 and 2.5 g / L of antibody are harvested by deep filtration and purified using an ALC column, in particular a Protein A column (GE Healthcare), according to the conditions described below in Table 1: Table 1 - Operating conditions for Protein A column

    * Res. Time = Residence time; **: CV, column volume.
    [0047] The balanced column is loaded with clarified harvest and is first washed with washing solution 1, described in Table 2 below, followed by a second washing with washing solution 2 (20 mM NaH2PO4 / Na2HPO4, pH 7.0) and then eluted at low pH. The eluate is analyzed for its antibody concentration by analytical ALC, for HMW / LMW by size exclusion analytical chromatography (SEC) and for the HCP content by an enzyme-linked immunosorbent assay, developed on the same cell line. The various washing solutions compared for the first wash are shown below in Table 2: Table 2 - Washing solutions for the first wash
    * pH adjusted with 32% NaOH solution.
    [0048] The percentage yields for Protein A purification of four different monoclonal antibodies (mAb), using the three different washing solutions shown in Table 2, are shown below in Table 3. Table 3 - Percentage Yields of Different Antibodies Using Various Washing Solutions

    [0049] Table 3 shows that washing with W1-A5 (containing no buffered salt or arginine, at pH 5.0) or W2-N7 (containing non-buffered salt, but not arginine at pH 7.0) results in fluctuations in the amount of antibody recovered depending on the antibody to be purified. More specifically, washing with W1-A5 results in yields ranging between 81 and 96% and washing with W2-N7 results in yields ranging between 92 and 101%. In contrast, washing with W3-Arg / N9, containing both non-buffered salt and arginine, at pH 9.0, results in consistently high yields, above 96%, for all four antibodies being purified.
    [0050] The eluate concentrations (in g / L), after Protein A purification from the four different mAbs, using the three different washing solutions shown in Table 2, are shown below in Table 4. Table 4 - Eluate Concentration Antibodies Using Multiple

    [0051] Table 4 shows that the eluate concentration is also influenced by the wash buffer applied during LAC. For three of the four mAbs (mAbs Qg, por and Va), washing with W3-Arg / N9 results in higher concentrations than washing with eluate W1-A5 or W2-N7. The average eluate concentration for the four antibodies is lower after washing W1-A5 (17.1 g / L), followed by washing W2-N7 (17.3 g / L) and higher after washing with W3-Arg / N9 (21.7 g / L).
    [0052] The reduction of host cell protein (HCP) in the eluates after purification of Protein A from the four different mAbs, using the three different washing solutions shown in Table 2, are shown below in Table 5. The reduction in HCP is expressed as the log reduction value (LRV) with respect to cell harvest values.

    [0053] With regard to the removal of impurities, based on the data in Table 5 a clear order can be established between the three wash buffers. The lowest HCP reduction is obtained with the low washing pH W1-A5, followed by washing with washing salt W2-N7 and the largest removal factor is obtained with the combination buffer of arginine-NaCl at pH 9.0 ( W3-Arg / N9). Expressed, in logarithmic order of removal, an average of 1.4 logs is obtained after washing with W1-A5, 1.55 logs with W2-N7 and the greatest removal of 2.2 logs is achieved with W3-Arg / N9.
    [0054] The level of high molecular weight species (HMW) in the eluates after Protein A Purification of the four different mAbs, using the three different washing solutions shown in Table 2, are shown below in Table 6. The level of species HMW in the eluates is expressed as a percentage (%) of the total protein in the eluates. Table 6 - Level of HMW Species in Eluate for Antibodies

    [0055] Table 6 shows that the level of HMW species is very heterogeneous for the 4 different mAbs and the removal of HMWs is dependent on mAb. In general, the washing solution W1-A5 is the least effective washing solution. Better results are obtained with the W2-N7 wash solution and the lower HMW values in the ALC eluate are consistently found with the W3-Arg / N9 wash solution. Three mAbs (mAbs Qg, By and Va) respond with a 2.6-5.9 fold reduction in HMWs comparing the W1- A5 wash versus the W3-Arg / N9 wash, whereas the mAb-Bp only showed a reduction marginal.
    [0056] A summary of the results for the experiments summarized in Tables 3-6 above is shown below in Table 7. The shaded line represents the composition of the production.
    Table 7 - Comparison of Three ALC Wash Solutions for Four mAbs 27/38 Conc. = Concentration of eluate; HCP = host cell protein; HMW = high molecular weight species; LRV = logarithmic reduction value; NA = not applicable. Petition 870200130491, of 10/16/2020, p. 30/48 Example 2: Comparison of Various Arginine / Salt Washing Solutions
    [0057] In this example, the effectiveness of the additional washing solutions, containing different amounts of non-buffered salt and / or arginine with different pH values, to remove impurities during liquid chromatography (ALC) affinity is compared. The chromatography conditions used in this Example are as defined in Table 8 below. Table 8 - Operating Conditions for Protein A Column
    * Res. Time = residence time; **: CV, column volume.
    [0058] The washing solutions compared in this Example are shown below in Table 9: Table 9 - Washing Solutions Additional Variants for the First Wash
    * The exact concentration was not measured (1 M Tris base [(hydroxymethyl) aminomethane] was used to adjust the pH).
    [0059] The four washing solutions indicated in Table 9 allow a direct comparison of a low uncapped saline solution (W4-N7 0.15 M, containing 150 mM NaCI) to a single unsalted saline solution ( W2-N7, containing 1M NaCI), as well as comparing a washing solution containing arginine alone, with pH 8.0 (W5-Arg8) to a washing solution containing the combination of non-buffered arginine with basic pH (W6 -Arg / N8).
    [0060] The percentage yield, the percentage HMW species in eIuato, and the HCP reduction (expressed as LRV) for the purification of mAb-By, using the four different washing solutions shown in Table 9, as well as the combination of Arginine washing alone (W5-Arg8) with the output washing alone (W2-N7), are shown below in Table 10. Table 10 - Purification Values for mAb Using Various Washing Solutions

    * LW = washing was performed for 12 column volumes instead of 6.
    [0061] Table 10 shows that the percentage yield of the antibody remains above 97% for all washing conditions. In addition, the most efficient washing solutions for removing impurities, both HMWs and HCPs, are the washing solution that contains both high buffered arginine salt with a basic pH (W6-Arg / N8) or the combined use of washing solutions containing arginine with basic pH (W5-Arg8) and high non-buffered salt (W2-N7).
    [0062] Washing with a washing solution instead of physiological, W4-N7 0.15 M, reduces HCPs by 64-times (1.81 logs) compared to the starting material that is loaded on the column. In contrast, washing with a non-buffered salt-arginine combination at pH 8 (W6-Arg / N8) results in a 498-fold reduction (2.7 logs).
    [0063] The reduction in HMWs follows a similar trend. Washing with the washing solution containing 20 mM sodium phosphate, 150 mM NaCl, pH 7.0 (0.15 M W4-N7) results in 1.6% HMWs in the eluate, while washing with the combination of non-buffered salt and arginine- (W6-Arg / N8) reduces this value by more than 5 times. Example 3: Comparison of Basic pH to Physiological pH in Washing Solutions
    [0064] In this example, an analysis of the pH as a parameter of the washing solutions on the removal of HCP and HMWs is conducted and shows the superiority of the basic pH conditions. Liquid affinity chromatography (ALC), using the conditions set out in Table 8 in Example 2, is performed on a cell collection of mAb-Va, with slightly different levels of HMW and HCPs.
    [0065] The washing solutions compared in this Example are shown below in Table 11: Table 11 - Washing Solutions with Variable pH Values for the First Wash (in mAb-Va)

    [0066] The percentage yield, the percentage eluate HMW species, and the HCP reduction (expressed as LRV) for the purification of mAb-Va, using the three different washing solutions shown in Table 11, are shown below in Table 12 Table 12 - Comparison of Physiological pH with Basic pH in Purification Values for mAb-Va

    [0067] The high non-buffered salt wash solution, alone, W2-N7, serves as a baseline control wash to establish the HCP / HMW removal capability of the pH 7 unginned salt / arginine combination, 0 approximately physiological (washing solution W6-Arg / N7) and with basic pH 8.9 (washing solution W3b-Arg / N8.9). A small but noticeable reduction in HMW levels 1.6-1.4% is observed at the highest pH (pH 8.9) compared to the lowest pH (pH 7.0). Most evident is the effect on HCP removal. Here, the washing solution at a lower pH (pH 7.0) reduces HCPs by 1.48 logs, while the high pH wash (pH 8.9) reduces the value by 1.61 logs, highlighting the superiority of washing pH high in the ability to remove impurities. Example 4: Comparison of Arginine / Salt Wash Solution with Other Wash Solutions
    [0068] In this example, other washing solutions, containing Tween 80, amino acids instead of arginine or high concentrations of Tris, are compared to the arginine / non-buffered salt washing solutions. In this example, an analysis of pH as a parameter of the washing solutions on the removal of PAC and HMWs is conducted and shows the superiority of the basic pH conditions. Liquid affinity chromatography (ALC), using the conditions set out in Table 1 in Example 1, is performed on a cell harvest of mAb-Va, with slightly different levels of HMW and HCPs.
    [0069] The washing solutions compared in this Example are shown below in Table 13: Table 13 - Washing Solutions with Variable Components for the First Wash
    * LW = washing was performed for 12 column volumes instead of 6. ** pH adjusted with 1M stock solution, conc. not measured.
    [0070] The percentage yield, the HMW percent eluted species, and the HCP reduction (expressed as LRV) for the purification of mAb-Va, using the six different washing solutions shown in Table 13, are shown below in Table 14 Table 14 - Comparison of Wash Solution Components on Purification Values for mAb-Va
    * LW = washing was performed for 12 column volumes instead of 6.
    [0071] Table 14 shows that the high pH non-buffered arginine / salt wash solution (W3b-Arg / N8.9) is the most efficient wash solution for removing both HMWs and HCPs, compared to other washing solutions containing high, non-buffered salt, alone (W2-N7), Tween 80 (W7-N7-T80), other amino acids such as glycine (W8-N7-0.1 mg) or high concentrations of tris (W9-0 , 5 M Tris 8.9 PV). Example 5: Comparison of Arginine Wash Solution / Non-Buffered Salt at High pH with Salt Alone at Low and High pH
    [0072] In this example, the effectiveness of the non-buffered arginine / salt washing solution at a high pH is compared with a non-buffered salt solution with high and low pHs. Specifically, the following conditions are evaluated and compared: (1) low pH (non-buffered) salt washing solution (ie 7.0), (2) high pH (non-buffered salt washing solution) , 9.0), and (3) non-buffered salt wash solution, in combination with arginine, with a high pH (i.e., 9.0). In addition, the effect of arginine on the removal of HMWs and LMWs and HCPs is analyzed, and shows that using the non-buffered salt solution in combination with arginine under basic pH conditions is particularly effective and advantageous. The washing solutions compared in this Example are shown below in Table 15: Table 15 - Washing Solutions with Variable Components for the First Wash
    * pH adjusted to 9.0 with 32% NaOH stock solution.
    [0073] Liquid affinity chromatography (ALC), using the conditions set out in Table 1 in Example 1, is performed on a mAb-By cell harvest, using different levels of HMWs and HCPs with minimal variations, as detailed below in the Table 16. Table 16 - Operating conditions for Protein A Column
    *, For the execution with washing solution W3-Arg / N9, 6 CV were used for balance reasons and 4 CV were used for elution and storage. **, Res. Time = residence time. ***, Tq = tel quel (as is).
    [0074] The parameters of (1) concentration of SEC derivative antibody (g / L), (2) percentage of HMW and LMW species, (3) level of HCP expressed in ng / mg of monoclonal antibody and, (4 ) percentage yield derived from ALC in the ALC eluate were measured for the purification of mAb-By, using the three different washing solutions shown in Table 15. The results are shown below in Table 17. Table 17 - Comparison of Wash Solution Components on Purification Values for mAb-By
    *, The second value corresponds to a second measurement after filtration through a 0.2 μm filter.
    [0075] Specifically, Table 17 shows that the high pH 9.0 non-buffered arginine / salt wash solution (W3-Arg / N9) is the most efficient wash solution for removing HMWs and LMWs and HCPs , in comparison with other washing solutions containing non-buffered salt alone (W2-N7 and N9-W10), regardless of their pH. In particular, washing with the non-buffered arginine / salt washing solution with a pH of 9.0 reduced HCPs at least three times and LMWs by at least four times compared to washing with salt not buffered alone with a pH of 7 (W2-N7) or a pH of 9 (W10-N9). Example 6: Comparison of Arginine and NaCl Concentration Ranges and pH for the Arginine / Salt Wash Solution
    [0076] In this example, additional arginine and non-buffering salt concentrations and pH washing conditions are investigated to determine their effectiveness in removing impurities during liquid affinity chromatography (ALC). The washing solutions compared in this Example are shown below in Table 18: Table 18 - Washing Solutions with Variable Components for the First Wash
    * pH adjusted with 8 M NaOH; ** buffer, obtained by 5-fold dilution of W13-Arg / N9 and adjusting the pH to 9.0 with 8 M NaOH.
    [0077] ALC is performed on a mAb-By cell harvest (under the conditions set out in Table 1 in Example 1), using slightly different levels of HMW and HCPs with minimal variations, as detailed below in Table 19. Table 19: Operating Conditions for Protein A Column (4 min Res. Time) +
    *, For execution with washing solution W11-Arg / N8,5; **, for execution with washing solution W12-Arg / N9,5; *** pH, adjusted with 1 M Tris; ****, to be executed with washing solution and W13-Arg / N9 W14-Arg / N9; pH *****, adjusted with 8 M NaOH. + Res. Time = residence time.
    [0078] The parameters of (1) SEC-derived antibody concentration (g / L), (2) percentage of HMW and LMW species (%), (3) HCP levels expressed in ng / mg monoclonal antibody, and (4) LAC-derived percentage yield in the LAC eluate was measured after purification of the mAb, using either of the two different washing solutions shown in Table 18. These results are shown below in Table 20. Table 20 - Wash buffer efficiency in different NaCl concentrations and pH levels for the purification of mAb-by (two different starting materials)

    [0079] The data presented in Table 20 highlight the effectiveness of the high pH non-buffered arginine / salt washing solution for use in liquid affinity chromatography. Washing with (1) arginine and a lower concentration of un-buffered salt (0.75 M NaCl) with a pH of 8.5, (2) arginine and a higher concentration of un-buffered salt (1.25 M NaCl) with a pH of 9.5 or (3) low (for example, 100 mM) or high (for example, 500 mM) concentrations of arginine, results in a strong reduction of HCPs (on average> 2 logs of reduction), without compromise performance.
    权利要求:
    Claims (14)
    [0001]
    1. Method of producing an antibody, antibody fragment or purified Fc fusion protein, using an affinity chromatography (AC) matrix to which the antibody, antibody fragment or Fc fusion protein is attached, said method characterized by the fact that it comprises: (a) loading a mixture comprising the antibody, antibody fragment or Fc fusion protein into the AC matrix; and (b) washing the AC matrix with a washing solution comprising (i) arginine and (ii) an un-buffered salt, where the pH of the washing solution is greater than 8.0, before eluting the antibody, antibody fragment or Fc fusion protein from the AC matrix.
    [0002]
    2. Method according to claim 1, characterized by the fact that the AC matrix is a Protein A column.
    [0003]
    3. Method according to claim 1 or 2, characterized by the fact that the wash removes impurities from the AC matrix.
    [0004]
    Method according to any one of claims 1 to 3, characterized in that it comprises: (a) loading a mixture comprising the antibody or antibody fragment on the Protein A column; (b) washing the Protein A column with a solution comprising (i) arginine at a concentration in the range of 0.05 to 0.85M; and (ii) sodium chloride at a concentration in the range of 0.1 to 2.0M, where the pH of the washing solution is greater than 8.0, and where the washing removes impurities from the Protein A column ; and (c) eluting the antibody or antibody fragment from the Protein A column.
    [0005]
    Method according to any one of claims 1 to 3, characterized by the fact that arginine is at a concentration in the range of 0.05 to 2.0 M.
    [0006]
    Method according to any one of claims 1 to 5, characterized in that the arginine is at a concentration of or about 0.25 M.
    [0007]
    Method according to any one of claims 1 to 5, characterized in that the arginine is arginine-HCl.
    [0008]
    Method according to any one of claims 1 to 7, characterized by the fact that the un-buffered salt is at a concentration in the range of 0.1 to 2.0 M.
    [0009]
    Method according to any one of claims 1 to 4, characterized in that the non-buffered salt is at a concentration of or about 1 M.
    [0010]
    10. Method according to any one of claims 1 to 4, characterized in that the non-buffered salt is sodium chloride (NaCl).
    [0011]
    11. Method according to any one of claims 1 to 5, characterized by the fact that the washing pH is in the range of about 8.5 to 9.5.
    [0012]
    12. Method according to any one of claims 1 to 5, characterized by the fact that the washing pH is 9.0.
    [0013]
    13. Method according to any one of claims 4 to 12, characterized in that the impurities comprise high molecular weight (HMW) species.
    [0014]
    14. Method according to any of claims 4 to 12, characterized in that the impurities comprise host cell proteins (HCPs).
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012014937B1|2021-01-19|method of producing an antibody, antibody fragment or purified fc fusion protein using an affinity chromatography matrix
    JP6366502B2|2018-08-01|Washing solutions and methods for affinity chromatography
    EP2649087A1|2013-10-16|Ion exchange chromatography in the presence of an amino acid
    AU2007204987B2|2011-11-24|Methods and systems for isolating target molecules from complex solutions by column-chromatography using eluants containing organic solvents
    Arakawa et al.2008|Solvent modulation of column chromatography
    Luo et al.2018|Evaluation of adsorption selectivity of immunoglobulins M, A and G and purification of immunoglobulin M with mixed-mode resins
    Arakawa et al.2009|Stress-free chromatography: affinity chromatography
    Holstein et al.0|Aggregate Removal and HCP Clearance Strategies using Protein A Resin
    同族专利:
    公开号 | 公开日
    EP3272764A1|2018-01-24|
    WO2011073389A1|2011-06-23|
    US20190233469A1|2019-08-01|
    RU2564569C2|2015-10-10|
    LT2513134T|2017-11-27|
    CN102725304B|2015-12-09|
    SG10201408384PA|2015-01-29|
    IL220164A|2019-02-28|
    CA2784278A1|2011-06-23|
    EP2513134A1|2012-10-24|
    PL2513134T3|2018-02-28|
    CN102725304A|2012-10-10|
    KR101858266B1|2018-05-15|
    DK2513134T3|2017-12-18|
    US20170044211A1|2017-02-16|
    AU2010332778B2|2015-03-19|
    AU2010332778A1|2012-07-19|
    ES2651065T3|2018-01-24|
    RU2012130151A|2014-01-27|
    US9505803B2|2016-11-29|
    BR112012014937A2|2016-03-08|
    PT2513134T|2017-12-14|
    MX2012007103A|2012-07-17|
    KR20120109506A|2012-10-08|
    CA2784278C|2019-02-26|
    EP2513134B1|2017-09-06|
    JP2013514073A|2013-04-25|
    US20120283416A1|2012-11-08|
    JP5909450B2|2016-04-26|
    JP2016128495A|2016-07-14|
    SG181771A1|2012-07-30|
    IL220164D0|2012-07-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4704366A|1984-06-22|1987-11-03|Bio-Rad Laboratories, Inc.|Process for binding IgG to protein A|
    JPH01238534A|1988-03-17|1989-09-22|Mitsui Toatsu Chem Inc|Removal of endotoxin|
    US5429746A|1994-02-22|1995-07-04|Smith Kline Beecham Corporation|Antibody purification|
    CA2271255C|1996-11-27|2011-06-14|Genentech, Inc.|Affinity purification of polypeptide on protein a matrix|
    KR100960211B1|1998-05-06|2010-05-27|제넨테크, 인크.|Protein Purification by Ion Exchange Chromatography|
    CA2333747C|1998-06-01|2008-02-19|Genentech, Inc.|Separation of protein monomers by use of ion-exchange chromatography|
    WO2002072615A1|2001-03-09|2002-09-19|Chugai Seiyaku Kabushiki Kaisha|Method of purifying protein|
    US7223848B2|2001-06-05|2007-05-29|Genetics Institute, Llc|Methods for purifying Fc-containing proteins|
    EP1472275B1|2002-02-05|2008-12-17|Genentech, Inc.|Protein purification|
    AU2003262087B2|2002-09-11|2010-11-11|Chugai Seiyaku Kabushiki Kaisha|Protein purification method|
    CA2503284A1|2002-10-24|2004-05-06|Enos Pharmaceuticals, Inc.|Sustained release l-arginine formulations and methods of manufacture and use|
    CN100369930C|2002-11-26|2008-02-20|Pdl生物制药股份有限公司|Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis|
    GB0304576D0|2003-02-28|2003-04-02|Lonza Biologics Plc|Protein a chromatography|
    CA2516518A1|2003-02-28|2004-09-10|Lonza Biologics Plc.|Antibody purification by protein a and ion exchange chromatography|
    NZ547315A|2003-10-27|2008-07-31|Wyeth Corp|
    US8084032B2|2004-01-21|2011-12-27|Ajinomoto Co., Inc.|Purification method which prevents denaturation of an antibody|
    DE602006003108D1|2005-03-03|2008-11-27|Ajinomoto Kk|Method for improving the yield in protein purification by gel filtration chromatography and arginine|
    HUE049797T2|2005-03-11|2020-10-28|Wyeth Llc|A method of weak partitioning chromatography|
    JP5530633B2|2006-01-06|2014-06-25|イー・エム・デイー・ミリポア・コーポレイシヨン|Affinity chromatography matrix and its production and use.|
    WO2007109163A2|2006-03-16|2007-09-27|Amgen Inc|Wash buffer and method of using|
    EP2001898A1|2006-03-20|2008-12-17|Medarex Inc.|Protein purification|
    CA2654181A1|2006-06-02|2007-12-13|Wyeth|Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods|
    US7754689B2|2006-06-02|2010-07-13|Wyeth Llc|Finger-1 peptide analogs of the TGF-β superfamily|
    ES2755386T3|2006-08-28|2020-04-22|Ares Trading Sa|Process for the purification of proteins containing Fc fragments|
    TW200821026A|2006-09-08|2008-05-16|Wyeth Corp|Arginine wash in protein purification using affinity chromatography|
    JP2010516651A|2007-01-17|2010-05-20|メルクセローノソシエテアノニム|Methods for purification of Fc-containing proteins|
    CA2687837A1|2007-06-01|2008-12-04|F. Hoffmann-La Roche Ag|Immunoglobulin purification|
    EP2281000A2|2008-05-15|2011-02-09|Novo Nordisk A/S|Antibody purification process|
    CN102171237A|2008-08-14|2011-08-31|默沙东公司|Methods for purifying antibodies using protein a affinity chromatography|
    ES2651065T3|2009-12-18|2018-01-24|Novartis Ag|Washing solution and method for affinity chromatography|
    CA2834300C|2011-06-01|2022-01-11|Novartis Ag|Wash solution and method for affinity chromatography|NZ597334A|2006-09-13|2014-02-28|Abbott Lab|Cell culture improvements|
    US8911964B2|2006-09-13|2014-12-16|Abbvie Inc.|Fed-batch method of making human anti-TNF-alpha antibody|
    KR101722423B1|2008-10-20|2017-04-18|애브비 인코포레이티드|Viral inactivation during purification of antibodies|
    JP5808249B2|2008-10-20|2015-11-10|アッヴィ・インコーポレイテッド|Antibody isolation and purification using protein A affinity chromatography|
    ES2651065T3|2009-12-18|2018-01-24|Novartis Ag|Washing solution and method for affinity chromatography|
    JP5567691B2|2010-01-22|2014-08-06|ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング|Chromatographic method for purifying Fc-containing proteins|
    CA2834300C|2011-06-01|2022-01-11|Novartis Ag|Wash solution and method for affinity chromatography|
    CN107266577A|2011-10-11|2017-10-20|弗·哈夫曼-拉罗切有限公司|The improved assembling of bispecific antibody|
    WO2014186350A1|2013-05-15|2014-11-20|Medimmune Limited|Purification of recombinantly produced polypeptides|
    MX2016002798A|2013-09-05|2016-07-21|Genentech Inc|Method for chromatography reuse.|
    CN105407905B|2014-01-03|2020-03-03|生物辐射实验室股份有限公司|Removal of impurities from protein A eluate|
    SG11201707330RA|2015-03-13|2017-10-30|Bristol-Myers Squibb Company|Use of alkaline washes during chromatography to remove impurities|
    ES2877532T3|2015-08-21|2021-11-17|Hoffmann La Roche|Procedure for the reduction of host cell proteins in affinity chromatography|
    US10513537B2|2016-05-11|2019-12-24|Ge Healthcare Bioprocess R&D Ab|Separation matrix|
    US10889615B2|2016-05-11|2021-01-12|Cytiva Bioprocess R&D Ab|Mutated immunoglobulin-binding polypeptides|
    US10654887B2|2016-05-11|2020-05-19|Ge Healthcare Bio-Process R&D Ab|Separation matrix|
    US10730908B2|2016-05-11|2020-08-04|Ge Healthcare Bioprocess R&D Ab|Separation method|
    CA3031028A1|2016-07-25|2018-02-01|Cephalon, Inc.|Affinity chromatography wash buffer|
    CN107793469B|2017-10-16|2021-07-30|上海药明生物技术有限公司|Affinity purification process for removing protein content of host cell|
    AU2018392697A1|2017-12-21|2020-08-06|Genzyme Corporation|Methods for enhanced removal of impurities during protein a chromatography|
    CN111902720A|2018-03-21|2020-11-06|沃特世科技公司|Non-antibody high affinity based sample preparation, adsorbents, devices and methods|
    MA52202A|2018-04-02|2021-02-17|Amgen Inc|COMPOSITIONS OF ERENUMAB AND USES OF THEM|
    WO2021072005A1|2019-10-08|2021-04-15|North Carolina State University|Immunoglobulin purification peptides and their use|
    WO2021191684A1|2020-03-27|2021-09-30|Haemalogix Pty Ltd|Composition and method|
    WO2021222120A1|2020-04-27|2021-11-04|Alexion Pharmaceuticals, Inc.|Protein a chromatography purification of an antibody|
    CN112827217A|2020-12-29|2021-05-25|苏州良辰生物医药科技有限公司|Chromatographic column cleaning solution and application thereof|
    法律状态:
    2019-01-08| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|
    2019-07-16| B07A| Technical examination (opinion): publication of technical examination (opinion)|
    2020-07-28| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law|
    2020-11-24| B09A| Decision: intention to grant|
    2021-01-19| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    US28805909P| true| 2009-12-18|2009-12-18|
    US61/288,059|2009-12-18|
    PCT/EP2010/070076|WO2011073389A1|2009-12-18|2010-12-17|Wash solution and method for affinity chromatography|
    [返回顶部]